WASHINGTON - The FDA's Cardiorenal Drugs Advisory Committee (CDAC) on Friday failed to support approval of Cor Therapeutics Inc.'s Integrilin GPIIb/IIIa inhibitor as an adjunct to angioplasty.

Although CDAC was convinced that the anti-platelet small molecule provided significant clinical benefit in preventing the sudden closure of blood vessels, the major complication associated with angioplasty, the members determined that the pivotal Phase III trial data presented by CORR (South San Francisco, Calif.) were not sufficiently persuasive to support approval.